Tempus announced an expanded, multi-year collaboration with Gilead, giving the pharma access to additional multimodal real-world cancer data and Tempus’s AI platform. The companies previously worked together using de-identified patient data to support trial design and biomarker-defined strategy development; the upgrade broadens the data types and analytics support available to Gilead. The deal highlights how large oncology portfolios are increasingly leveraging “queryable” data libraries and AI-driven cohort exploration to accelerate R&D decisions.